Respiratory therapy

Global Asthma Market and Competitive Landscape 2014-2018 & 2023: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, and Market Shares

Retrieved on: 
Friday, October 26, 2018
Economy, Business, Asthma, Respiratory therapy, Management, Market share, Forecasting

The "Global Asthma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Asthma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Asthma Market and Competitive Landscape - 2018, provides comprehensive insights into Asthma pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • This study accurately estimates and forecast Asthma market size and drug sales.
  • The research is classified into following sections - Asthma overview with definitions, symptoms, etiology, diagnosis, treatment options; Asthma pipeline insights covering late stage clinical trials pipeline; Asthma prevalence trends by countries; Asthma market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.

Pneuma Respiratory, Inc. Announces J. Knox Singleton Joins the Board of Directors

Retrieved on: 
Friday, October 26, 2018
Dosage forms, Asthma, Pneuma, Vitalism, Respiratory therapy, Inhaler, Health, Medicine

BOONE, N.C., Oct. 26, 2018 /PRNewswire/ -- Pneuma Respiratory, Inc., which has developed PNEUMAHALER, the first breath-activated digital inhaler (BDI), announced its Board of Directors has elected shareholder J. Knox Singleton to the Board.

Key Points: 
  • BOONE, N.C., Oct. 26, 2018 /PRNewswire/ -- Pneuma Respiratory, Inc., which has developed PNEUMAHALER, the first breath-activated digital inhaler (BDI), announced its Board of Directors has elected shareholder J. Knox Singleton to the Board.
  • Mr. Singleton has received numerous awards during his career in recognition of his leadership in the field of health care.
  • "We are honored to have Knox join our Board," stated Pneuma Chief Executive Officer and Co-founder Eric Hunter.
  • With a global team of researchers, physicians, designers and engineers, Pneuma has created PNEUMAHALER, the first fully integrated digital breath activated inhaler.

Ventilators (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model

Retrieved on: 
Friday, October 26, 2018
Medicine, Health, Respiratory therapy, Intensive care medicine, Emergency medicine, Mechanical ventilation, Medical ventilator, Intensive care unit, Intensivist

Ventilators (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Anesthesia & Respiratory Devices therapeutic area.

Key Points: 
  • Ventilators (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Anesthesia & Respiratory Devices therapeutic area.
  • Modern respiratory ventilators strive to ensure patient safety and improve ventilation outcomes, while providing portable and cost-effective solutions in a variety of clinical settings.
  • Mechanical ventilators dominate the ventilation devices market, due to their effective functionalities and advanced features.Due to the large installed base in intensive care units (ICU) and increasing numbers of ICU admissions, the market for critical care ventilators leads the ventilators market with a steady growth.
  • - Annualized total Ventilators market revenue by segment and market outlooks from 2015-2028.

Peak Flow Meters (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model

Retrieved on: 
Friday, October 26, 2018
Economy, Respiratory therapy, Business, Asthma, Medical equipment, Peak expiratory flow, Business intelligence, Strategic management, SWOT analysis, Flow measurement, Market analysis

Peak Flow Meters (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Anesthesia & Respiratory Devices therapeutic area.

Key Points: 
  • Peak Flow Meters (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Anesthesia & Respiratory Devices therapeutic area.
  • Peak Flow Meters are simple and low-cost devices to measure the peak expiratory flow with consistent readings.They are commonly used in hospital, outpatient and domiciliary settings.
  • - Annualized total Peak Flow Meters market revenue by segment and market outlooks from 2015-2028.
  • - SWOT analysis for Peak Flow Meters market.

Airway Management Tubes (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model

Retrieved on: 
Thursday, October 25, 2018
Medicine, Clinical medicine, Health care, Airway management, Anesthesia, Respiratory therapy, Intensive care medicine, Mechanical ventilation, Advanced airway management

Airway Management Tubes (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Anesthesia & Respiratory Devices therapeutic area.

Key Points: 
  • Airway Management Tubes (Anesthesia & Respiratory Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Anesthesia & Respiratory Devices therapeutic area.
  • Non-surgical procedures include the airway management for patients with acute respiratory failure, inadequate oxygenation and intensive care needs.
  • - Annualized total Airway Management Tubes market revenue by segment and market outlooks from 2015-2028.
  • - SWOT analysis for Airway Management Tubes market.

Visiongain Report Offers Transformative Insights on $38bn Respiratory Inhalers Market

Retrieved on: 
Thursday, October 25, 2018
Medicine, Dosage forms, Health, Clinical medicine, Asthma, Respiratory therapy, Dry-powder inhaler, Inhaler

The global respiratory inhalers market reached $33bn in 2017 and is estimated to reach $38bn by 2023.

Key Points: 
  • The global respiratory inhalers market reached $33bn in 2017 and is estimated to reach $38bn by 2023.
  • In 2017, the asthma segment held 58% of the global respiratory inhalers market.
  • The 165-page report provides clear detailed insight into the respiratory inhalers market.
  • Forecast of the Global Respiratory Inhalers market by Type of Product:
    Dry Powder Inhalers (DPIs): Single-dose DPIs, Multi-dose DPIs
    Forecast of the Global Respiratory Inhalers market by Indication:

MedLearn Publishing Launches Educational Webcast to Benefit Respiratory Therapy Professionals

Retrieved on: 
Tuesday, October 23, 2018
Respiratory therapy, Health, Medicine, American Association for Respiratory Care, Respiratory therapist, AARC

ST. PAUL, Minn., Oct. 23, 2018 /PRNewswire-PRWeb/ --MedLearn Publishing has produced a singularly unique new webcast designed to benefit professionals working in the field of respiratory therapy, company officials announced this week.

Key Points: 
  • ST. PAUL, Minn., Oct. 23, 2018 /PRNewswire-PRWeb/ --MedLearn Publishing has produced a singularly unique new webcast designed to benefit professionals working in the field of respiratory therapy, company officials announced this week.
  • Titled the "2019 Respiratory Therapy Reimbursement and Compliance Update," the webcast is currently available online via this link: https://shop.medlearn.com/rt_compliance_update_training_p/art.htm .
  • The webcast has been approved for 1.5 contact hours of Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care (AARC).
  • MedLearn Publishing is a nationally recognized healthcare publishing and media firm specializing in all aspects of coding, compliance, reimbursement, and the revenue cycle.

FDA Approves Asthma Indication for Dupixent® (dupilumab)

Retrieved on: 
Monday, October 22, 2018
Neurochemistry, Medicine, Clinical medicine, RTT, Respiratory therapy, Asthma, Chloroarenes, Sodium channel blockers, Ketamine, Reslizumab, Mepolizumab

For people with asthma, Dupixent comes in two doses (200 mg and 300 mg) given every other week at different injection sites after an initial loading dose.

Key Points: 
  • For people with asthma, Dupixent comes in two doses (200 mg and 300 mg) given every other week at different injection sites after an initial loading dose.
  • Dupixent is currently under regulatory review for moderate-to-severe asthma in several other countries, including Japan and in the European Union (EU).
  • If you are taking asthma medicines, do not change or stop your asthma medicine without talking to your healthcare provider.
  • with other asthma medicines for the maintenance treatment of moderate-to-severe asthma in people aged 12 years and older whose asthma is not controlled with their current asthma medicines.

FDA Approves Asthma Indication for Dupixent® (dupilumab)

Retrieved on: 
Friday, October 19, 2018
Neurochemistry, Medicine, Clinical medicine, RTT, Respiratory therapy, Asthma, Chloroarenes, Sodium channel blockers, Ketamine, Reslizumab, Mepolizumab

For people with asthma, Dupixent comes in two doses (200 mg and 300 mg) given every other week at different injection sites after an initial loading dose.

Key Points: 
  • For people with asthma, Dupixent comes in two doses (200 mg and 300 mg) given every other week at different injection sites after an initial loading dose.
  • Dupixent is currently under regulatory review for moderate-to-severe asthma in several other countries, including Japan and in the European Union (EU).
  • If you are taking asthma medicines, do not change or stop your asthma medicine without talking to your healthcare provider.
  • with other asthma medicines for the maintenance treatment of moderate-to-severe asthma in people aged 12 years and older whose asthma is not controlled with their current asthma medicines.

Digital Landscape: Asthma

Retrieved on: 
Wednesday, October 17, 2018
Health, Respiratory therapy, Economy, Asthma, Pharmaceutical industry, Digital strategy

LONDON, Oct. 17, 2018 /PRNewswire/ -- Digital Landscape: Asthma

Key Points: 
  • LONDON, Oct. 17, 2018 /PRNewswire/ -- Digital Landscape: Asthma
    "Digital Landscape: Asthma", analyzes digital activities undertaken by pharma industry in support of therapies for asthma.
  • - US Patients: Strong feature-rich branded sites for both inhaled and injectable asthma therapies in the US.
  • - This report analyzes digital activities undertaken by pharma in support of therapies for asthma.
  • - Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital asthma space, and can assist our pharma clients derive value in a number of ways:
    - Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
    - Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
    - Business Development & Licensing: Assess topics and trends shaping digital health in asthma and beyond, and learn about key patient and physician online activities in asthma.